Stay updated on OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.

Latest updates to the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page
- Check5 days agoChange DetectedRevision label in the site footer updated from v3.3.1 to v3.3.2.SummaryDifference0.1%

- Check13 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and may not be about the study, and updated the page revision to v3.3.1; removed the older PubMed-sourced sentence and the Revision: v3.2.0.SummaryDifference0.1%

- Check20 days agoChange DetectedDeleted the government funding/operating status notice that used to appear at the bottom of the page. The notice described potential delays in updates and NIH facility operations.SummaryDifference0.4%

- Check34 days agoChange DetectedExternal links to PubMed and U.S. government sites were removed from the page footer. The core study details and page structure remain unchanged.SummaryDifference0.3%

- Check41 days agoChange DetectedThe page now includes new external references, including a PubMed publication (40598566), and links to government sites such as HHS, NIH, NLM, NCBI, and USA.gov. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check63 days agoChange DetectedUpdated system to revision v3.2.0 and added a government operating status notice; removed the previous No Results Posted and v3.1.0 references.SummaryDifference4%

Stay in the know with updates to OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.